Infermedica, a digital health company specializing in artificial intelligence-powered preliminary diagnosis and triage solutions, has raised $30 million in a Series B funding round, the company announced Wednesday (Jan. 26).
This round was led by One Peak, the London-based venture capital company that invests in tech-enabled companies in Europe. The financing was also supported by previous investors: European Bank for Reconstruction and Development, Heal Capital, Karma Ventures and Inovo Venture Partners. The latest investment brings the company’s total funding to $44 million.
The Denver-based HeathTech said the capital will be used to support development of their medical guidance platform and add other modules to cover a patient’s primary care journey.
“We will deploy the new funds to execute our vision of making primary care more efficient and affordable by creating constantly improving AI technology for everyone on the planet,” said CEO Piotr Orzechowski in a statement.
Co-founded by Orzechowski in Poland a decade ago, the team grew by 80% last year to include 180 specialists, physicians, scientists and engineers, the company said. The firm said it expects to double their workforce in 2022.
Infermedica is available in 30 countries and used by more than 90 healthcare organizations and partners, the company said. The company’s mission is to make healthcare accessible, affordable and convenient by automating primary care, from symptom to treatment.
COVID-19 lockdowns have forced people to seek alternative ways to access health services, triggering a boom in the use of technology and innovation in healthcare provision worldwide.
Read more: Global HealthTech Sector Continues to Grab Investor Interest In 2022
As a result, investments in global health technology startups have skyrocketed since the onset of the pandemic, to $51.3 billion in 2021, increasing 280% from 2016, according to recent data from London & Partners (LP) and Dealroom.co.
With investments starting to pour in this year, that trend is likely to continue, especially as uncertainty around the pandemic’s end continues.
We’re always on the lookout for opportunities to partner with innovators and disruptors.
Learn More